阿卡拉布替尼

阿卡拉布替尼（CAS 1420477-60-6）的公开数据库记录，列此仅供独立核对。

危险化学品分类与危害说明

法规与备案状态

物理形态与操作说明

• Freely soluble in water at pH values below 3 but is practically insoluble in water at pH values above 6
• Acalabrutinib is a Bruton Tyrosine Kinase inhibitor that prevents the proliferation, trafficking, chemotaxis, and adhesion of B cells. It is taken every 12 hours and can cause other effects such as atrial fibrillation, other malignancies, cytopenia, hemorrhage, and infection.

公开数据库收录的理化数据

这个物质在各数据库里的编号

数据库记载的用途

• Acalabrutinib is indicated for: - The treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy. - The treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. - In combination with [rituximab] and [bendamustine] for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).
• Acalabrutinib is an oral inhibitor of Bruton’s tyrosine kinase that is used in the therapy of B cell malignancies including refractory mantle cell lymphoma and chronic lymphocytic leukemia. Acalabrutinib has been associated with mild-to-moderate serum enzyme elevations during therapy but has not been linked to instances of idiosyncratic acute liver injury, although it has been associated with cases of reactivation of hepatitis B which can be severe and even fatal.
• Breast Feeding; Lactation; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors; Tyrosine Kinase Inhibitors;
• Acalabrutinib Maleate Monohydrate
• Acalabrutinib maleate monohydrate is approved to treat adults with:
• • Chronic lymphocytic leukemia or small lymphocytic lymphoma.

它在各数据库里的别名

Acalabrutinib; 1420477-60-6; ACP-196; acalabrutinibum; 4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide; I42748ELQW; CHEBI:167707; DTXSID401026209; 4-[8-Amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinylbenzamide; 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide; 4-(8-Amino-3-((2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl)imidazo(1,5-a)pyrazin-1-yl)-N-2-pyridinylbenzamide; 4-(8-amino-3-((2S)-1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo(1,5-a)pyrazin-1-yl)-N-(pyridin-2-yl)benzamide; 4-(8-amino-3-((2S)-1-but-2-ynoylpyrrolidin-2-yl)imidazo(1,5-a)pyrazin-1-yl)-N-pyridin-2-ylbenzamide; RefChem:57414; L01XE51; DTXCID401510462

计算机算出的分子描述符

数据库摘要

Acalabrutinib · CAS 1420477-60-6 · C26H23N7O2. UNII I42748ELQW. LogP: 0.49.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。